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Abstract Primary dissociated fetal mouse spinal cord cultures
were used to study the mechanisms underlying the differences in
persistence of botulinum neurotoxin A (BoNT/A) and botulinum
neurotoxin/E (BoNT/E) activities. Spinal cord cultures were
exposed to BoNT/A (0.4 pM) for 2^3 days, which converted
approximately half of the SNAP-25 to an altered form lacking
the final nine C-terminal residues. The distribution of toxin-
damaged to control SNAP-25 remained relatively unchanged for
up to 80 days thereafter. Application of a high concentration of
BoNT/E (250 pM) either 25 or 60 days following initial
intoxication with BoNT/A converted both normal and BoNT/
A-truncated SNAP-25 into a single population lacking the final
26 C-terminal residues. Excess BoNT/E was removed by
washout, and recovery of intact SNAP-25 was monitored by
Western blot analysis. The BoNT/E-truncated species gradually
diminished during the ensuing 18 days, accompanied by the
reappearance of both normal and BoNT/A-truncated SNAP-25.
Return of BoNT/A-truncated SNAP-25 was observed in spite of
the absence of BoNT/A in the culture medium during all but the
first 3 days of exposure. These results indicate that proteolytic
activity associated with the BoNT/A light chain persists inside
cells for s 11 weeks, while recovery from BoNT/E is complete in
6 3 weeks. This longer duration of enzymatic activity appears to
account for the persistence of serotype A action.
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1. Introduction
The botulinum neurotoxins (BoNTs) comprise a family of
highly lethal protein toxins that act by selectively inhibiting
the release of acetylcholine at the neuromuscular junction and
autonomic ganglia [1^3]. The toxins are produced by strains
of the anaerobic bacterium Clostridium botulinum and are re-
sponsible for foodborne, infant and wound botulism [1^3].
Seven immunologically distinct serotypes of BoNT are known
and are designated in the order of their discovery as A^G
[1,2]. In their active form, these clostridial neurotoxins are
dichain proteins associated by a single disul¢de bond [4].
The larger subunit (heavy chain, V100 kDa) mediates toxin
binding and internalization; the smaller subunit (light chain,
V50 kDa) possesses zinc metalloprotease activity and cleaves
one of three proteins involved in the docking and release of
synaptic vesicles: synaptobrevin, syntaxin and SNAP-25 [5^7].
BoNT/A and E cleave SNAP-25 near its C-terminus, remov-
ing nine and 26 residues, respectively [8].
Although BoNT/A and E both target SNAP-25, the two
serotypes di¡er markedly in duration of action. Intoxication
by serotype E is relatively short-lived, whereas paralysis
caused by serotype A is persistent, lasting for up to 6 months
[9,10]. The persistence of BoNT/A has led to its use in a
variety of muscle tone and movement disorders [11].
The basis for di¡erences in paralysis times is not well under-
stood. It may re£ect di¡erences in the stability of the respec-
tive light chains in the nerve terminal or di¡erences in the
inherent toxicity of SNAP-25 cleavage products [12]. Consis-
tent with the latter proposal, Ferrier-Monteil et al. [13] found
that a synthetic peptide identical to the 26-mer BoNT/E cleav-
age product inhibits transmitter release in bovine chroma⁄n
cells and in Aplysia buccal ganglia driver cells. This peptide
appears to act by forming a non-productive fusion complex
with the synaptic vesicle protein synaptobrevin and the active
zone protein syntaxin [13].
Evidence in support of the former proposal has been ob-
tained by sequential local injections of BoNT/A and E in rat
extensor digitorum longus muscle [14]. Injection of BoNT/A
before or after BoNT/E led to paralysis times that were con-
trolled by BoNT/A rather than by BoNT/E. These data sug-
gest that the duration of toxicity is determined by the lifetime
of active BoNT/A.
A more direct test of the factors underlying toxin persis-
tence would require monitoring the lifetime of BoNT or of the
state of SNAP-25 in the nerve terminal. Detection of BoNT is
inherently di⁄cult due to the paucity of intracellular toxin
[15], whereas monitoring of SNAP-25 is impractical in skeletal
muscle since the nerve terminal comprises only a small pro-
portion of the total muscle protein. To overcome these limi-
tations, we used primary fetal spinal cord cultures to study the
mechanisms underlying di¡erences in persistence of BoNT/A
and E. The results indicate that proteolytic activity associated
with the BoNT/A light chain persists inside cells for over
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11 weeks while recovery from BoNT/E is complete within
3 weeks. This longer duration of enzymatic activity appears
to account for the persistence of serotype A action.
2. Materials and methods
2.1. Materials
Monoclonal antibodies to SNAP-25 and syntaxin were obtained
from Sternberger Monoclonals, Inc. (Baltimore, MD, USA) and Sig-
ma Chemical Co. (St. Louis, MO, USA), respectively. The polyclonal
anti-mouse antibody conjugated to alkaline phosphatase was also
purchased from Sigma. All electrophoresis reagents were from Bio-
Rad (Hercules, CA, USA). Polyvinylidene di£uoride membrane
(PVDF) was obtained from either BioRad (0.2 Wm) or Sigma
(0.4 Wm). Non-fat dry milk was from Nestle Food Co. (Glendale,
CA, USA).
2.2. Animals
Timed pregnant C57BL/6J mice were obtained from the Frederick
Cancer Research and Development Center, Frederick, MD, USA.
Animals were rendered unconscious in a CO2 atmosphere and decapi-
tated. Embryos were surgically removed from the amniotic sac, de-
capitated and the spinal cords were isolated for preparation of dis-
persed cell cultures.
2.3. Cell culture
Spinal cord cell cultures were prepared as described [16,17]. Brie£y,
spinal cords were removed from fetal mice at gestation day 13, dis-
sociated with trypsin and plated on Vitrogen coated dishes (Collagen
Corp., Palo Alto, CA, USA) at a density of 106 cells/dish. Cultures
were maintained for 3 weeks at 37‡C in an atmosphere of 90% air/10%
CO2 before addition of toxins. Cultures were grown in Eagle’s mini-
mum essential medium (formula 82-0234AJ; Life Technologies Inc.,
Bethesda, MD, USA) supplemented with 5% heat-inactivated horse
serum and a mixture of complex factors [18].
2.4. Preparation of protein extracts, gel electrophoresis and Western
blot analysis
2.4.1. Preparation of total protein. Protein was prepared by dis-
solving cells in a 1% SDS solution. The slurry was transferred to 1.5-
ml microfuge tubes, incubated in a 95‡C water bath for 10 min to
inactivate proteases and stored at 330‡C. Protein concentration was
determined by a modi¢cation of the bicinchoninic method (Pierce
Chemical Co., Rockford, IL, USA). Samples were mixed with equal
volumes of SDS-reducing bu¡er (2% SDS, 5% L-mercaptoethanol,
55 mM Tris-Cl, pH 6.8, 10% glycerol and 0.05% bromophenol blue)
and heated at 95‡C for 5 min immediately prior to separation by SDS-
polyacrylamide gel electrophoresis (SDS-PAGE).
2.4.2. Gel electrophoresis and Western blotting. Equal quantities of
protein were loaded onto 16.5% acrylamide gels by the method of
Laemmli [19]. Proteins were separated using 0.1 M Tris-Tricine as
run bu¡er (pH 8.3) [20] then transferred to PVDF membrane using
192 mM glycine, 25 mM Tris, pH 8.3 and 7% methanol.
The PVDF membrane was treated with Tris-bu¡ered saline block-
ing bu¡er (TBS blocker: 0.5 M NaCl, 25 mM Tris, pH 7.5 containing
4% non-fat dry milk) for 1 h. Primary antibodies in blocking bu¡er
were incubated with the membrane at 30‡C using gentle agitation for
90 min followed by two sequential 10-min washes with TTBS (TBS
containing 0.05% Triton X-100) at room temperature. A secondary
antibody conjugated to alkaline phosphatase was similarly applied to
the membrane, followed by two sequential washes with TTBS, one
wash with TBS and a 1-min rinse with deionized water before visual-
izing the bound alkaline phosphatase with 5-bromo-4-chloro-3-indolyl
phosphate and nitro blue tetrazolium solution (Sigma). Antibodies
were diluted 1:1000 in blocking bu¡er prior to use.
2.5. Botulinum neurotoxin preparation
Preparations of BoNT/A and E toxin complex were from Wako
Chemicals (Richmond, VA, USA) with reported activities of
2.0U107 LD50 per mg. BoNT/E (1 mg/ml) was activated (nicked)
by incubating for 30 min at 37‡C with 0.3 mg/ml trypsin (type XI,
bovine pancreas) in 30 mM HEPES, pH 6.75 [21]. Soybean trypsin
inhibitor type I-S (0.5 mg/ml) was added in the same bu¡er and
incubated at room temperature for 15 min to inhibit further trypsini-
zation. Toxin was aliquoted and stored at 330‡C. Stock solutions of
BoNT/A (1 mg/ml) were diluted to 100 nM in a solution consisting of
200 mM NaCl and 50 mM Na acetate (pH 6.0), aliquoted and stored
at 330‡C. Each experiment utilized a new aliquot of toxin to ensure
uniform activity. Molar concentrations stated in the text where based
upon masses of 500 and 300 kDa for BoNT/A and E, respectively.
Toxins were dissolved in supplemented MEM, and cultures were in-
cubated with BoNT for 18^72 h, as appropriate. BoNT-containing
media was removed by aspiration; cells were rinsed with toxin-free
MEM then fed with 2 ml of control supplemented MEM. Feeding
then resumed to half-changes of supplemented MEM twice weekly.
2.6. Data analysis
Scanned images of Western blots were produced and stored utiliz-
ing Photoshop (Adobe Systems, Inc., Mountain View, CA, USA).
When indicated, images were digitally analyzed using ONE-Dscan
gel analysis software (Scanalytics, Inc., Fairfax, VA, USA). Densito-
metric values were plotted using non-linear regression analysis
(GraphPad Prism 3.0, San Diego, CA, USA). Error bars represent
one standard deviation of triplicate determinations.
3. Results
3.1. Speci¢c proteolysis by BoNT/A and E
Fig. 1 demonstrates proteolysis of SNAP-25 by BoNT/A
and E in cultured mouse spinal cord cells by Western blot
analysis. Control cells contained abundant SNAP-25 (lane
1), which was contributed almost exclusively by the neuronal
component of the cultures; glia have been reported to be
devoid of SNAP-25 [22,23]. Incubation of cultures with
0.4 pM BoNT/A for 48 h led to cleavage of approximately
50% of the total neural SNAP-25 (lane 2). BoNT/A-truncated
SNAP-25 has an apparent molecular weight of 24 kDa, due to
loss of a 9-mer fragment from cleavage between Q197 and
R198 (Table 1) [24]. Incubation of spinal cord cells with
36 pM BoNT/E produced an approximately equal degree of
proteolysis of SNAP-25 (lane 3). The resulting BoNT/E-trun-
cated SNAP-25 was smaller (22 kDa), since a 26-mer frag-
ment was removed by speci¢c cleavage between amino acids
R180 and I181 (Table 1) [25]. The SNAP-25 antibody recog-
nizes the N-terminal region, and therefore the nine and 26
C-terminal cleavage products could not be resolved in this
study.
Fig. 1. Speci¢c proteolysis of SNAP-25 after exposure of mouse spi-
nal cord cell cultures to BoNT/A or E. Protein samples were pre-
pared as described in Section 2 and subjected to SDS-PAGE under
reducing conditions. The sample in lane 1 shows a band at approxi-
mately 25 kDa corresponding to SNAP-25 from untreated cells.
Cultures treated for 48 h with either 0.4 pM BoNT/A (lane 2) or
36 pM BoNT/E (lane 3) exhibit approximately 50% proteolysis of
SNAP-25. Production of the 24- and 22-kDa fragments (Table 1) is
indicative of appropriate BoNT activity. The Western blot was
screened using a monoclonal antibody that recognizes the same epi-
tope on all three forms of SNAP-25. The smaller cleavage products
of BoNT/A and E action do not appear in this or subsequent blots
since the antibodies do not recognize the C-terminal region of
SNAP-25.
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3.2. Recovery of SNAP-25 from BoNT/E-mediated proteolysis
To determine the recovery of SNAP-25 following BoNT/E-
mediated proteolysis, spinal cord neurons were exposed to
BoNT/E, washed with control medium to remove excess toxin
and monitored for restoration of intact SNAP-25 during
18 days in culture. The results of a representative experiment
are shown in Fig. 2A. Under control conditions, a single
25 kDa band was apparent for SNAP-25 (lane 1). Following
exposure to 116 pM BoNT/E for 18 h, nearly complete cleav-
age of SNAP-25 was evident (lane 2). Upon removal of excess
toxin, a time-dependent recovery of intact SNAP-25 and dis-
appearance of BoNT/E-altered SNAP-25 were observed (lanes
3^7). Recovery of intact SNAP-25 was rapid, such that nearly
20% of control density returned within 1 day and 90% recov-
ery was evident 7 days after cells were returned to control
medium (half-time = 5.8 days) (Fig. 2B). The disappearance
of BoNT/E-truncated SNAP-25 occurred at a similar rate;
approximately half of this toxin-altered protein disappeared
within 4.6 days and little was apparent after 18 days of BoNT/
E exposure.
3.3. Recovery of SNAP-25 from BoNT/A-mediated proteolysis
Unlike the relatively rapid restoration of intact SNAP-25
following BoNT/E exposure, little recovery of SNAP-25 was
observed subsequent to BoNT/A intoxication. For evaluating
BoNT/A, a low toxin concentration was selected to ensure
that the slow recovery could not be attributed to excess intra-
cellular toxin. As evident from the Western blots (Fig. 3A)
and densitometric analysis (Fig. 3B), exposure of cultures to
0.4 pM BoNT/A resulted in approximately 40% cleavage of
SNAP-25 after 3 days; little recovery of intact SNAP-25 or
disappearance of BoNT/A-altered SNAP-25 was observed
over an 80-day period (Fig. 3B). The persistence of serotype
A action in spinal cord cultures was even more pronounced
than that observed in rat EDL muscle after a paralytic dose of
BoNT/A [9,10,14]. In the latter preparation, 42% of the con-
trol twitch tension returned 30 days after a local i.m. injection
of BoNT/A [14]. These results suggest that recovery of muscle
tension after BoNT/A is due largely to formation of new
synapses rather than to restoration of function in BoNT/A-
intoxicated nerve terminals [26].
3.4. Recovery of SNAP-25 from sequential application of
BoNT/A and BoNT/E
The continued presence of BoNT/A-truncated SNAP-25
observed in Fig. 3 may re£ect a static intracellular condition
where SNAP-25 synthesis and degradation are both inhibited,
or alternatively, it demonstrates persistent BoNT/A enzymatic
activity. To gain insight into underlying the di¡erences in
persistence of BoNT/A and E on cleavage of SNAP-25, ex-
periments were performed in which cells were incubated se-
quentially in BoNT/A and E, and SNAP-25 recovery rates
were monitored at 43 and 78 days after addition of BoNT/
A. Fig. 4 shows the results of two such studies. Addition of
0.4 pM BoNT/A for 72 h resulted in cleavage of V50% of
SNAP-25, which was undiminished 25 days later (Fig. 4, lane
1). Excess BoNT/A was removed by washout with control
medium and cultures were maintained as before. Twenty-¢ve
days after exposure to BoNT/A, cells were incubated in
250 pM BoNT/E (Fig. 4A, lane 2); consequently, both intact
and 24 kDa BoNT/A-truncated SNAP-25 were converted to
the 22 kDa BoNT/E-truncated form. The BoNT/E-truncated
SNAP-25 diminished over the next 13 days (Fig. 4A, lanes 3^
5) and was only detectable in trace amounts by day 18 (Fig.
4A, lane 6). The time-course for elimination of the BoNT/E-
altered SNAP-25 was similar following sequential toxin addi-
tion (illustrated here) as it was after exposure to BoNT/E
alone (Fig. 2).
In parallel with the disappearance of the BoNT/E-truncated
SNAP-25, intact and BoNT/A-altered SNAP-25 returned in
preparations subjected to sequential serotype intoxication.
Signi¢cantly, this occurred with no re-exposure to BoNT/A
(Fig. 4A, lanes 3^6). During this period, both normal and
BoNT/A-truncated SNAP-25 were found to increase in inten-
sity. The rate of recovery of intact SNAP-25 was initially
more rapid than the return of BoNT/A-truncated SNAP-25,
but by day 18, the distribution of these proteins resembled
that encountered prior to addition of BoNT/E (Fig. 4A, lanes
1 and 6).
Fig. 4B shows the results of a similar experiment in which
BoNT/E addition was delayed for 60 days following exposure
to BoNT/A (Fig. 4B). The apparent rate of synthesis of intact
SNAP-25 and degradation of BoNT/E-truncated SNAP-25
Table 1
SNAP-25 sequence
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were relatively unchanged from those observed 4 weeks earlier
(Fig. 4A). Even with these later time points, reappearance and
accumulation of BoNT/A-truncated SNAP-25 was observed
as the abundance of new SNAP-25 increased (Fig. 4B, lanes
3^5). The relative proportion of BoNT/A-truncated to total
SNAP-25, however, was only approximately half as much
following 11 weeks of exposure to BoNT/A (Fig. 4B, lane 6)
as it was after 6 weeks of exposure (Fig. 4A, lane 6).
The return of intact SNAP-25 indicates that active synthesis
of this protein continues during the period of BoNT intoxi-
cation. The reappearance of BoNT/A-truncated SNAP-25
long after initial exposure to BoNT/A suggests that a fraction
of newly synthesized SNAP-25 is cleaved by residual BoNT/A
proteolytic activity. These ¢ndings are important, since they
indicate that BoNT/A remains catalytically active in neurons
with no observable decrease in activity for at least 43 days
after initial exposure and only an approximate 2-fold decrease
after 78 days.
4. Discussion
The clostridial neurotoxins, which include the seven sero-
types of BoNT and tetanus toxin, are among the most potent
substances known [1^3]. These toxins comprise a novel family
of zinc metalloproteases with remarkable speci¢city for their
target proteins [6]. Serotype A is further distinguished by hav-
ing an exceptionally long duration of action [9,14], a key
factor in its use for treatment of an increasing number of
dysfunctions of muscle tone and movement [11]. The long
duration of action of BoNT/A, however, renders management
of systemic intoxication by this serotype especially di⁄cult
because individuals exposed to BoNT/A often require ex-
tended periods of arti¢cial ventilation and intensive care [1^
3]. The prolonged duration of BoNT/A action also creates
problems arising from its potential military use, since phar-
macological therapies would have to be maintained for the
entire period of intoxication.
The basis for persistence of BoNT/A action is poorly under-
stood. Two possibilities include (1) a continuous action of
BoNT/A or of its catalytically active light chain in the nerve
terminal, or (2) toxicity of one or both cleavage products of
SNAP-25 [12,13]. An association between prolonged toxicity
and continuous action of BoNT/A is readily apparent,
although the mechanisms permitting prolonged survival of
BoNT enzymatic activity in eukaryotic neurons would be nov-
el.
Toxicity from the persistence of cleavage products is less
obvious. Gutierrez et al. [12] observed that small 20^26-mer
Fig. 3. A: Persistence of BoNT/A-truncated SNAP-25. Spinal cord
cell cultures were treated with 0.4 pM BoNT/A for 48 h, which had
been determined previously to cleave half of the SNAP-25 popula-
tion. Excess toxin was removed by aspiration and replaced with
growth medium; cultures were probed for SNAP-25 and syntaxin
periodically during the next 80 days to monitor recovery. The levels
of intact and BoNT/A-altered SNAP-25 were unaltered, suggesting
an absence of recovery during the period of observation. B: Rela-
tive abundance of the 24-kDa SNAP-25 fragment produced by
BoNT/A action over time. The percent of damaged SNAP-25 was
calculated from the ratio of band intensities of BoNT/A-truncated
SNAP-25 to total SNAP-25 at each time point. There is no statisti-
cally signi¢cant decrease in the amount of intact or damaged
SNAP-25 over the 80-day period (P6 0.05). Each bar represents the
average of band densities from three Western blots.
Fig. 2. Time-course for recovery of SNAP-25 following BoNT/E in-
cubation. A: Exposure of spinal cord cell cultures to 116 pM
BoNT/E for 18 h produced extensive cleavage of SNAP-25 (lane 2);
116 pM BoNT/E was the lowest concentration that produced near
total loss of SNAP-25. To monitor recovery, toxin-containing me-
dium was removed by aspiration and replaced with control growth
medium; cultures were probed for SNAP-25 and syntaxin at 0.75,
3, 7, 11 and 18 days with anti-syntaxin and anti-SNAP-25 monoclo-
nal antibodies; syntaxin remained unchanged while SNAP-25 levels
increased progressively. B: Densitometric analysis of intact and
BoNT/E-altered SNAP-25. The observed half-times for recovery of
intact SNAP-25 (F) and elimination of BoNT/E-truncated SNAP-25
(R) were 5.8 and 4.6 days, respectively. The values for synthesis
were expressed relative to the band at zero time; values for degra-
dation were expressed relative to the 22-kDa band at day 0.75.
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SNAP-25 peptides were able to inhibit the release of noradre-
nalin from permeabilized chroma⁄n cells by up to 70%. This
action has been suggested to arise from the ability of these
peptides to form non-productive fusion complexes with com-
ponents of the vesicle docking and release apparatus [12,13].
The 24 kDa cleavage product has also been shown to inhibit
release: in this case insulin secretion from a neuroendocrine
cell line, presumably by competing with normal SNAP-25
[27].
The two mechanisms are not mutually exclusive, since con-
tinuous proteolysis of SNAP-25 by BoNT/A may be required
to produce sustained concentrations of cleavage products. It is
unlikely that, in the absence of continuous BoNT enzymatic
activity, SNAP-25 fragments can persist for the observed du-
ration of intoxication (Fig. 3). Evidence that at least some
cleavage products degrade rapidly was shown in Fig. 2, where
the 22 kDa BoNT/E-truncated SNAP-25 disappeared with a
half-time of 4.6 days. The actual degradation rate is likely to
be more rapid since new 22 kDa cleavage products are ex-
pected to add to the existing pool until BoNT/E activity
ceases.
In the case of BoNT/A, the continued presence of the 24
kDa fragment observed in Fig. 3 may arise by one of two
possible mechanisms: (1) BoNT/A activity is brief but the
24 kDa fragment escapes degradation, or (2) BoNT/A is sig-
ni¢cantly more stable than BoNT/E and acts continuously to
cleave new SNAP-25 for the 80-day period of observation
(Fig. 4B). If the ¢rst hypothesis is correct, the apparent equal
distribution of the 24 kDa fragment relative to intact SNAP-
25 (Fig. 3) requires concomitant block of SNAP-25 synthesis
and inhibition of its degradation. However, the results shown
in Fig. 4 demonstrate that SNAP-25 synthesis continues in the
presence of both serotypes, and that return of SNAP-25 is
followed by the reappearance of the 24-kDa fragment. Fur-
thermore, because the 24-kDa fragment does not accumulate
with time (Fig. 3) but appears to reach a steady-state with
synthesis of intact SNAP-25, the 24-kDa fragment must be
degraded at a rate similar to the turnover rate of intact
SNAP-25. It would thus be di⁄cult to conceive of a mecha-
nism that would maintain the BoNT/A cleavage products for
a time su⁄cient to account for the observed 80-day period in
the absence of its continuous production (Fig. 2). Based on
the above, inhibition of transmitter release from accumulation
of cleavage products can account for only a fraction of the
inhibition that is observed in the presence of toxin; the re-
mainder must arise from the loss of SNAP-25 and the con-
sequent impairment of vesicle fusion at productive release
sites.
To attempt to quantify the contribution of the cleavage
fragments to toxicity, precise knowledge of turnover rates is
needed to determine the intracellular lifetimes of these prod-
ucts. However, detailed information of the rates of synthesis
or degradation of SNAP-25 or its cleavage fragments is not
presently available. The data in Fig. 2, for example, represents
¢ve separate processes: normal SNAP-25 synthesis and deg-
radation, production and degradation of the 22-kDa SNAP-
25 fragment, and loss of BoNT/E activity. Because these
events could not be measured independently in the present
study, our interpretations are con¢ned to upper limit esti-
mates. The actual rate of SNAP-25 synthesis, for example,
may be faster than the observed half-time of 5.8 days in the
absence of residual BoNT/E activity. Likewise, the observed
degradation of the 22-kDa fragment may be slower than the
actual rate because of residual BoNT/E activity.
Independent data for SNAP-25 degradation in the rabbit
optic nerve demonstrated a half-time for degradation of 3 to 5
days with only trace amounts of labeled SNAP-25 remaining
16 days later [28]. As synthesis and degradation of intact
SNAP-25 reaches a point of mass balance, new SNAP-25
must be synthesized at the same rate as it is degraded. Inter-
estingly, the observed rate of synthesis for new SNAP-25 and
degradation of the BoNT/E-truncated SNAP-25 occur at sim-
ilar rates within experimental error, implying that BoNT/E is
completely inactivated within 24 h of exposure.
A recent report by Eloepra et al. [29] indicated that in
human volunteers, co-injection of BoNT/A and E results in
rapid recovery of muscle tension similar to injections with
BoNT/E alone. The authors concluded that both serotypes
had equally short lifetimes, but paralysis was due to very
slow degradation and inhibitory action of the 24-kDa
SNAP-25 fragment. A brief lifetime for BoNT/A is not sup-
ported by the results in Fig. 4, which clearly indicate that
BoNT/A action is prolonged. The di¡erences between the
present results and those of Eloepra et al. [29] may be due
to species di¡erences in the degradation of SNAP-25 cleavage
products. Alternatively, co-injection of both serotypes may
selectively block BoNT/A from entering the nerve terminal.
The experiments in Fig. 4 provide the clearest demonstra-
tion to date for the persistence of active BoNT/A after intro-
duction of a relatively low concentration by showing the re-
Fig. 4. Sequential additions of BoNT/A and E to demonstrate per-
sistent action of BoNT/A. Cells were exposed to 0.4 pM BoNT/A
for 72 h after which BoNT/A-containing medium was aspirated and
replaced with control growth medium. Lane 1 represents 25 (A) or
60 (B) days after BoNT/A exposure. A: Cultures were exposed to
250 pM BoNT/E for 24 h, whereupon both intact and BoNT/A-
truncated SNAP-25 were converted into the BoNT/E-altered form
(lane 2). During the ensuing 18 days, increases were observed in in-
tact and BoNT/A-truncated SNAP-25, while the BoNT/E-truncated
SNAP-25 gradually disappeared (lanes 3^6). The high concentration
of BoNT/E ensured complete proteolysis of both intact and BoNT/
A-altered SNAP-25; the low BoNT/A concentration ensured that
the long recovery times did not result from overloading cells with
BoNT/A. B: Similar experiment as in A. but BoNT/E was added
for 24 h 60 days after exposure to BoNT/A (lane 2). In spite of the
longer residence time of BoNT/A, synthesis of intact SNAP-25 and
accumulation of BoNT/A-truncated SNAP-25 continued to be ob-
served (lanes 3^6). In each case, the return of BoNT/A-altered
SNAP-25 indicates persistent activity of intracellular BoNT/A.
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turn of BoNT/A-truncated cleavage product long after BoNT/
A exposure (Fig. 4B). Furthermore, the ratio of damaged to
normal SNAP-25 was maintained for at least 43 days after the
onset of BoNT/A exposure (Fig. 4A) and decreased only
slightly 78 days thereafter (Fig. 4B). Fig. 4 also shows that
SNAP-25 synthesis continues in spite of the presence of both
toxins. This direct demonstration of SNAP-25 synthesis indi-
cates that degradation of the 24-kDa fragment must be rela-
tively rapid (Fig. 2). If this were not the case, the 24-kDa
cleavage product would become more abundant as synthesis
of new SNAP-25 proceeded. Since the 24-kDa fragment did
not continue to accumulate over time (Fig. 3), it suggests that
the major factor limiting recovery is prolonged stability of
BoNT/A rather than depressed synthesis of SNAP-25 or sup-
pressed degradation of cleavage fragments.
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